🔗 Share this article

As the United States continues making historic changes to its immunization guidelines, a particular individual appears somewhat surprisingly: Tracy Beth Høeg, a US-based physician and epidemiologist who initially gained attention by casting doubt on coronavirus vaccines during the pandemic and has concentrated on alleged fatalities following COVID-19 immunization in her brief time at the FDA.

Proposed Shifts to Childhood Vaccine Schedule

Health officials planned to announce radical changes to the childhood immunization program in December, aligning the US with the Danish immunization schedule, according to reports – a major change that would place the US out of step with a large portion of the international standard with no evidence for improved outcomes. The announcement has been postponed until the new year.

In place of Vinay Prasad, Dr. Høeg is scheduled to speak at the meeting. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the division this calendar year.

A Shift at the Regulatory Body

Høeg's temporary position might represent a closer partnership between the drug and vaccine divisions as Høeg and Dr. Prasad solidify control at the regulatory agency – and it signals a greater focus upon reevaluating long-standing vaccines at the FDA.

Høeg has often pushed for discontinuing some pediatric immunization guidelines in the US to become more in line with the Danish model, a country with universal health coverage and a number of inhabitants about the population of the state of Wisconsin.

So far public appearances, she has kept her attention on vaccination policy – typically the domain of Dr. Prasad, director of the FDA’s vaccine center – rather than medication approval.

Questions Over Qualifications

Høeg has little discernible background in drug development, oversight or management, which has been typical for previous directors of the CBER. She has worked at the FDA as a top consultant to the commissioner and the vaccine center since earlier this year.

“It seems she lacks to have any of the qualifications” for leading the drug-regulation department, said a neurologist and psychiatrist. “She has not conducted a randomized controlled trial. She lacks experience in running a sizeable institution. She lacks background in pharmaceutical oversight.”

Former commissioners of CBER would “be deeply familiar with legal statutes and the science of drug development”, said Dr. Janet Woodcock. “Frankly, she lacks the kind of background that prior appointees who headed the center have had.”

CDER has an enormous range of responsibilities at the agency, the former commissioner stated.

“Everybody just pays attention on the new drug program, but the generic drug division approves thousands of generic drugs. There is also a biosimilars program, non-prescription drug unit and other areas, and all of those have to be looked after,” Dr. Woodcock explained. “The thing you neglect, that’s the thing that I always told people is going to cause problems.”

Additionally, a significant leadership element to the position, which supervises in excess of 5,000 personnel. “It’s a huge management job, if you perform it correctly,” Woodcock added.

Response and Controversial Policies

Regarding questions about Dr. Høeg's credentials and whether this appointment represents increased cooperation among agency officials on vaccines, a press secretary said that the “inquiries rely on inaccurate premises”.

“This background aligns with the duties of her role,” the representative stated, citing the months Dr. Høeg spent guiding the agency head on “pharmaceutical safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Dr. Høeg inherits the commissioner’s recently launched priority voucher program, a contentious expedited drug-approval program that reportedly concerned her predecessors. “How are these therapies being selected for this voucher program? Who is making the choices?” Dr. Howard said. “There is a lot of lack of transparency going on at the FDA right now.”

In general, he said, “the FDA seems to be moving towards laxer regulations of pharmaceuticals, aside from shots.”

Established Past Work on Vaccines

Regarding vaccines, Høeg has a clearer, if troubling, track record, some experts have noted. She authored a analysis using unverified volunteer-provided data to assess the frequency of heart inflammation after Covid immunization. She counseled the state of Florida top health official Dr. Joseph Ladapo, who reportedly have altered data to indicate COVID-19 vaccinations are riskier than they are.

Included in her “desired changes” for the incoming government included revising guidelines for recently developed shots and discontinuing “optional” immunizations, she said after the election on a online show. At the agency, Dr. Høeg has reportedly floated the idea of preventing adolescent males from getting COVID-19 vaccines.

“She’s an thorough ideologue who commences with her preconceived notions and tailors the evidence to fit the science in a very misleading, untruthful fashion,” Dr. Howard stated.

Consolidating Power and a “Push for Payback”

Dr. Høeg became part of other contrarians, {like|